177Lu-iPSMA is the therapeutic analogue of 99mTc-iPSMA developed at the Instituto Nacional de Investigaciones Nucleares (ININ) and the National Cancer Institute of Mexico City, Mexico. This molecule is an additional possibility in the treatment of metastasized prostate cancer patients with a mechanism based on PSMA.

A first publication came out in 2018 describing the first preclinical results and the first data generated with volunteers and patients on the basis of imaging with 99mTc-iPSMA. No new information has been released in the meantime.

Target/Mechanism: PSMA

Leading Emitter: beta electrons (β–)